GLPwatch
Papers (9189)
Page 37 of 154, ranked by citation count.
- Evaluation of the INS-1 832/13 cell line as a beta-cell based screening system to assess pollutant effects on beta-cell function.
- 99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma.
- Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation.
- Current Drug Targets in Obesity Pharmacotherapy - A Review.
- Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis.
- PET-Based Human Dosimetry of <sup>68</sup>Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging.
- Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery.
- Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice.
- Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
- Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations.
- Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres.
- Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway.
- Effect of anti-hyperglycemic drugs on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells.
- Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies.
- Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus.
- The incretin hormones: from scientific discovery to practical therapeutics.
- In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
- Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
- Exendin-4 Induces Bone Marrow Stromal Cells Migration Through Bone Marrow-Derived Macrophages Polarization via PKA-STAT3 Signaling Pathway.
- The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials.
- Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-α pathway.
- Genetically Encoded Cholesterol-Modified Polypeptides.
- Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
- Near-infrared fluorescent probe for imaging of pancreatic beta cells.
- The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose.
- Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States.
- Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes.
- GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy.
- Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.
- Semaglutide and the risk of diabetic retinopathy-current perspective.
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes.
- Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells.
- Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells.
- Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling.
- Pancreatic islet cells disarray, apoptosis, and proliferation in obese mice. The role of Semaglutide treatment.
- Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.
- The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review.
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
- Obesity and GLP-1.
- Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
- Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats.
- Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 Diabetes.
- p38<i>β</i> Mitogen-Activated Protein Kinase Signaling Mediates Exenatide-Stimulated Microglial <i>β</i>-Endorphin Expression.
- Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats.
- Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?
- Obesity and weight management in the elderly: a focus on men.
- Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
- Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome.
- Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.
- Development of chitosan coated calcium-alginate nanocapsules for oral delivery of liraglutide to diabetic patients.
- Liposome-encapsulated clodronate specifically depletes spinal microglia and reduces initial neuropathic pain.
- Liraglutide Inhibits the Apoptosis of MC3T3-E1 Cells Induced by Serum Deprivation through cAMP/PKA/β-Catenin and PI3K/AKT/GSK3β Signaling Pathways.
- Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism.
- Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages.
- What have we learnt from "real world" data, observational studies and meta-analyses.
- Therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury.
- The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.
- Liraglutide ameliorates palmitate-induced endothelial dysfunction through activating AMPK and reversing leptin resistance.
- Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells.
- Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent.